NovaSight Study Highlights Superiority of CureSight Over Traditional Patching in Amblyopia Treatment

NovaSight, a rapidly expanding pediatric eyecare company, announced the publication of a study demonstrating that its CureSight digital eye-tracking device significantly improves visual acuity (VA) in amblyopia patients compared to traditional patching. The study, published in the American Journal of Ophthalmology, involved 149 children and showed that those adhering to the CureSight regimen achieved greater VA gains and higher adherence rates.

The per-protocol dataset (n=54) revealed that the CureSight group had a mean distance VA improvement of 2.8 lines, which is 0.53 lines higher than the patching group. Median adherence in the CureSight group was 94%, compared to 83.9% in the patching group. The CEO of NovaSight, Ran Yam, emphasized the study as a significant milestone building on previous research proving CureSight's effectiveness.

Dr. Nicholas Sala, a clinical investigator, expressed satisfaction with the device, noting its effectiveness and appeal to children. NovaSight also announced recent Chinese NMPA approval for CureSight, further expanding its global reach, following U.S. FDA clearance and European CE Mark.